← All organizations
Highest phase reached
Phase 3
First clinical trial
Dec 1, 2004First marketed drug
Apr 22, 2024First NDA
Apr 22, 2024Last known activity
Apr 22, 2024
Acquired by NantCell, Inc. → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks → ImmunityBio, Inc. → NantWorks on Jun 27, 2017
Timeline
2000s
- Jun 1, 2002
Altor Bioscience— Founded
2010s
- Jun 27, 2017
NantCell, Inc.— Acquired By
2020s
- Dec 21, 2020
NantWorks— Now
- Apr 22, 2024
nogapendekin alfa inbakicept— NDA Organization
Drugs by trial phase (24 distinct, 21 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (15 own, 0 via acquisition)
Phase 1 (7 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Merkel Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Colorectal Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Injury
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Melanoma
- Microsatellite Instability
- Multiple Myeloma
- Neoplasms
- Neoplasms, Plasma Cell
- Pancreatic Neoplasms
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Sepsis
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Syndrome
- Ureteral Neoplasms
- Urethral Neoplasms
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
- Wounds and Injuries
Marketed drugs (1)
Recent trials (32)
- NCT04290546CollaboratorPhase 1Mar 31, 2020
- NCT03228667Lead sponsorPhase 2Jun 30, 2018
- NCT03520686Lead sponsorPhase 2May 18, 2018
- NCT03381586Lead sponsorPhase 1Jan 8, 2018
- NCT03003728CollaboratorPhase 2Aug 1, 2017
- NCT03022825Lead sponsorPhase 2/Phase 3Jun 2, 2017
- NCT02559674Lead sponsorPhase 1/Phase 2Jul 1, 2016
- NCT02559674Study chairPhase 1/Phase 2Jul 1, 2016
- NCT02523469CollaboratorPhase 1/Phase 2Jan 1, 2016
- NCT02384954Lead sponsorPhase 1/Phase 2Mar 1, 2015
- NCT02384954Study chairPhase 1/Phase 2Mar 1, 2015
- NCT02099539Lead sponsorPhase 1/Phase 2Sep 1, 2014
- NCT02099539Study chairPhase 1/Phase 2Sep 1, 2014
- NCT02138734Lead sponsorPhase 1/Phase 2Jul 1, 2014
- NCT02138734Study chairPhase 1/Phase 2Jul 1, 2014
Details
- Founded
- Miramar, FL, US Jun 1, 2002
- First NDA
- Apr 22, 2024
- Last known activity
- Apr 22, 2024
Designations held
- Fast track
- Breakthrough therapy
Notes
Spun out from Sunol Molecular Corp